Basis of Presentation and Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 07, 2017	Dec. 31, 2016
Noncontrolling Interest [Line Items]
Accumulated deficit	$ 65,714,314		$ 65,714,314			$ 57,004,655
Net loss	2,300,807	$ 1,616,946	8,709,659	$ 9,101,770
Grant received for preclinical activities from CPRIT	500,000		900,000
Non-controlling interest	$ 203,371	$ 47,042	344,328	$ 329,471
Pelican Therapeutics, Inc. [Member]
Noncontrolling Interest [Line Items]
Net loss			$ (100,000)
Percentage of voting interests acquired in acquisition	80.00%		80.00%		80.00%
Grant received for preclinical activities from CPRIT			$ 15,200,000
Non-controlling interest	$ 164,802		$ 179,253
Heat Biologics I, Inc. [Member]
Noncontrolling Interest [Line Items]
Ownership interest in subsidiary	92.50%		92.50%			92.50%
Non-controlling interest	$ 38,569		$ 165,075